# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-043698
Filing Date
2024-10-18
Accepted
2024-10-18 16:11:03
Documents
4
Period of Report
2024-11-14

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ny20036093x2_def14a.htm | DEF 14A | 149139
2 | GRAPHIC | logo_oruka.jpg | GRAPHIC | 37750
3 | GRAPHIC | ny20036093x2_pc01.jpg | GRAPHIC | 549872
4 | GRAPHIC | ny20036093x2_pc02.jpg | GRAPHIC | 568514
| Complete submission text file | 0001140361-24-043698.txt |  | 1742014

Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-22873 | Film No.: 241380856
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)